Five Swiss startups have made Hello Tomorrow's Top 100 Deep Tech ranking for 2026, while three more—PeelPack, BitVault and Reilo—have secured places in international accelerator programs, in a run of ...

VERAXA Biotech AG aims to establish the premiere drug discovery and development engine for antibody drug conjugates and other novel antibody-based therapy concepts. The company’ ...

Following an initial announcement in April regarding an IPO via SPAC, Terra Quantum has now presented a new plan involving a different shell company and has slightly increased its target valuation to ...

Over 11 years, SwissVC grew into a network of more than 500 venture capital professionals across Switzerland, Europe and the US. "The old model created energy, but not enough oper ...

AInesHR, a Zürich-based startup developing an AI-native HR platform for companies operating across multiple European ...

Three years ago, Bionomous launched its novel EggSorter, which is now used in academic institutions, contract research organisations (CROs) and pharmaceutical companies around the world.

The Swiss Venture Capital Report 2026 offers key insights into the latest trends shaping the investment landscape. Download the report in our assets section. Use the Dashboard to analyse the data.

To bring these benefits to the operational scale, Voltiris and Genson will install almost 2,000 modules, covering 1 hectare in Genson's state-of-the-art strawberry greenhouse.

Following approval of its first spinal Carbon/PEEK implants in the US, it took icotec only a few years to achieve annual sales of more than USD 50 million. To finance its continued development, the ...

For the second time, the Demo Day of the HSG START Accelerator brought together investors, partners, and a large number of guests to listen to the presentations of eight selected ...

Founded in 2010, curli develops and sells dog harnesses known for their high level of comfort, low weight, and user-friendly features. The company is based in Switzerland and had ...

HAYA Therapeutics dosed the first cohort in a Phase 1 cardiac fibrosis trial, Mabylon reported positive Phase 1a safety results for its peanut allergy candidate, Molecular Partners published Phase 1 ...